An observational study in Adverse Pregnancy Outcomes and Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Regeneron Pharmaceuticals · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals — 1 open to participants now, 2 under way, none of them phase 3. Dermatitis, Atopic · Regeneron Pharmaceuticals.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the only one that started in 2019, is one of 5 observational ones, and was the 24th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals is open now, in 2 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Belgium
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 10 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2019.
This study's enrollment of 12,343 is above the median of 150 across 284 observational studies indexed under Dermatitis, Atopic.
Median enrollment 194 across the 25 interventional studies, 581 across the 5 observational. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
1 of the studies in Dermatitis, Atopic by Regeneron Pharmaceuticals that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03428646Regeneron PharmaceuticalsStudy of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) | 2027-03-30 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations [MCMs], small for gestational age [SGA]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Adult women with AD who are pregnant between 01 April 2017 and 31 March 2024 (with the start of pregnancy to be defined by the estimated last menstrual period (LMP))
Key Inclusion Criteria:
Note: Other Protocol Defined Inclusion / Exclusion Criteria Apply
Exposed to dupilumab during the relevant exposure window: * First trimester * Pregnancy
Drug: dupilumab
Exposed to systemic medications other than dupilumab or to phototherapy during the relevant exposure window: * First trimester * Pregnancy
* Not exposed to systemic medications (including dupilumab) or phototherapy; and * Received topical prescription therapy, or a second diagnosis for AD on a date that differs from the base population qualifying AD diagnosis date during the relevant exposure window: * First trimester * Pregnancy
No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
Also known as: REGN668, Dupixent®, SAR23189
Prevalence of MCMs
Initially identified through the presence of corresponding codes on the insurance claims, confirmed through medical record review for infant outcomes: 01 April 2017 through December 2024
Time frame: Up to 21 months
Incidence of spontaneous abortion or miscarriage
Identified through the presence of corresponding codes on the insurance claims for pregnancy outcomes: 01April 2017 through 31 March 2024
Time frame: Up to 9 months
Incidence of stillbirth
Identified through the presence of corresponding codes on the insurance claims for pregnancy outcomes: 01April 2017 through 31 March 2024
Time frame: Up to 9 months
Incidence of SGA
Identified through the presence of corresponding codes on the insurance claims for infant outcomes: 01 April 2017 through December 2024
Time frame: Up to 21 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Apr 2026, 78 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jan 2027 → Apr 2026 and completion Jan 2027 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.